| 28/08/25 | GSK | 07:00:08 | 28 Aug 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 27/08/25 | GSK | 07:00:06 | 27 Aug 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 26/08/25 | GSK | 07:00:08 | 26 Aug 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 22/08/25 | GSK | 07:00:03 | 22 Aug 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 21/08/25 | GSK | 15:30:00 | 21 Aug 2025 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 21/08/25 | GSK | 07:00:07 | 21 Aug 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 20/08/25 | GSK | 07:00:06 | 20 Aug 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 19/08/25 | GSK | 15:30:01 | 19 Aug 2025 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 19/08/25 | GSK | 07:00:05 | 19 Aug 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 18/08/25 | GSK | 07:00:05 | 18 Aug 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 15/08/25 | GSK | 07:00:06 | 15 Aug 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 14/08/25 | GSK | 07:00:03 | 14 Aug 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 13/08/25 | GSK | 07:00:08 | 13 Aug 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 12/08/25 | GSK | 15:30:01 | 12 Aug 2025 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 12/08/25 | GSK | 07:00:05 | 12 Aug 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 11/08/25 | GSK | 07:00:09 | 11 Aug 2025 | | GSK | FDA to review gonorrhea indication for gepotidacin | GSK PLC | RNS |
| 11/08/25 | GSK | 07:00:07 | 11 Aug 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 08/08/25 | GSK | 07:00:11 | 8 Aug 2025 | | GSK | CureVac/BioNTech mRNA patent litigation settlement | GSK PLC | RNS |
| 08/08/25 | GSK | 07:00:05 | 8 Aug 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 07/08/25 | GSK | 07:00:06 | 7 Aug 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 06/08/25 | GSK | 07:00:04 | 6 Aug 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 05/08/25 | GSK | 07:00:09 | 5 Aug 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 04/08/25 | GSK | 07:00:07 | 4 Aug 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 01/08/25 | GSK | 15:00:01 | 1 Aug 2025 | | GSK | Total Voting Rights | GSK PLC | RNS |
| 01/08/25 | GSK | 07:00:06 | 1 Aug 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 31/07/25 | GSK | 07:00:09 | 31 Jul 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 30/07/25 | GSK | 07:05:01 | 30 Jul 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 30/07/25 | GSK | 07:00:06 | 30 Jul 2025 | | GSK | 2nd Quarter Results | GSK PLC | RNS |
| 29/07/25 | GSK | 07:00:05 | 29 Jul 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 28/07/25 | GSK | 07:00:07 | 28 Jul 2025 | | GSK | GSK enters Hengrui Pharma collaboration agreements | GSK PLC | RNS |
| 28/07/25 | GSK | 07:00:05 | 28 Jul 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 25/07/25 | GSK | 07:00:04 | 25 Jul 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 24/07/25 | GSK | 17:00:00 | 24 Jul 2025 | | GSK | Blenrep approved in the EU for multiple myeloma | GSK PLC | RNS |
| 24/07/25 | GSK | 07:00:05 | 24 Jul 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 23/07/25 | GSK | 17:00:01 | 23 Jul 2025 | | GSK | US FDA review extended for Blenrep | GSK PLC | RNS |
| 23/07/25 | GSK | 07:00:05 | 23 Jul 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 22/07/25 | GSK | 07:00:05 | 22 Jul 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 21/07/25 | GSK | 07:00:07 | 21 Jul 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 18/07/25 | GSK | 15:30:01 | 18 Jul 2025 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 18/07/25 | GSK | 07:00:05 | 18 Jul 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 18/07/25 | GSK | 07:00:02 | 18 Jul 2025 | | GSK | Blenrep US ODAC outcome | GSK PLC | RNS |
| 17/07/25 | GSK | 07:00:06 | 17 Jul 2025 | | GSK | GSK’s Shingrix Fully Liquid FDA approval | GSK PLC | RNS |
| 17/07/25 | GSK | 07:00:06 | 17 Jul 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 16/07/25 | GSK | 07:00:05 | 16 Jul 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 15/07/25 | GSK | 15:30:00 | 15 Jul 2025 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 15/07/25 | GSK | 07:00:04 | 15 Jul 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 14/07/25 | GSK | 15:30:00 | 14 Jul 2025 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 14/07/25 | GSK | 07:00:11 | 14 Jul 2025 | | GSK | GSK submits Arexvy for adults 18-49 AIR to FDA | GSK PLC | RNS |
| 14/07/25 | GSK | 07:00:07 | 14 Jul 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 11/07/25 | GSK | 07:00:05 | 11 Jul 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |